Publication | Year | ||||||||
---|---|---|---|---|---|---|---|---|---|
Abstract IA009: Development of HIF2 inhibitors: Bench to bedside and back Authors : James BrugarolasJournal : Cancer Research Volume : 83 Pages : IA009-IA009 |
2023 | ||||||||
The expanding role of BAP1 in clear cell renal cell carcinoma Authors : Payal Kapur , Satwik Rajaram , James BrugarolasJournal : Human Pathology Journal Reference count : 76 Volume : 133 Pages : 22-31 |
2023 | ||||||||
Reporting on FH-deficient renal cell carcinoma using circulating succinylated metabolites Authors : Divya Bezwada , James BrugarolasJournal : Journal of Clinical Investigation Journal Reference count : 15 Volume : 133 |
2023 | ||||||||
Authors :
Payal Kapur
, James Brugarolas
, Kiril Trpkov
Journal : Cancers Journal Reference count : 125 Volume : 15 Pages : 4043 |
2023 | ||||||||
The von Hippel-Lindau Tumor Suppressor Gene Authors : Roy Elias , Qing Zhang , James BrugarolasJournal : The Cancer Journal Journal Reference count : 133 Volume : 26 Pages : 390-398 |
2020 | ||||||||
Authors :
Tri Cao Le
, James Brugarolas
Journal : Journal of Clinical Oncology Volume : 35 Pages : e16070-e16070 |
2017 | ||||||||
Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma Authors : James BrugarolasJournal : Journal of the National Comprehensive Cancer Network Volume : 14 Pages : 925-927 |
2016 | ||||||||
Molecular Genetics of Clear-Cell Renal Cell Carcinoma Authors : James BrugarolasJournal : Journal of Clinical Oncology Journal Reference count : 88 Volume : 32 Pages : 1968-1976 |
2014 | ||||||||
Authors :
Samuel Peña-Llopis
, James Brugarolas
Journal : Nature Protocols Journal Reference count : 42 Volume : 8 Pages : 2240-2255 |
2013 | ||||||||
PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma Authors : James BrugarolasJournal : The Cancer Journal Journal Reference count : 102 Volume : 19 Pages : 324-332 |
2013 | ||||||||
TFEB, a novel mTORC1 effector implicated in lysosome biogenesis, endocytosis and autophagy Authors : Samuel Peña-Llopis , James BrugarolasJournal : Cell Cycle Journal Reference count : 11 Volume : 10 Pages : 3987-3988 |
2011 | ||||||||
Authors :
Lisa Kinch
, Nick V. Grishin
, James Brugarolas
Journal : Cancer Cell Journal Reference count : 10 Volume : 20 Pages : 418-420 |
2011 | ||||||||
Authors :
Jing Zhou
, James Brugarolas
, Luis F. Parada
Journal : Human Molecular Genetics Journal Reference count : 38 Volume : 18 Pages : 4428-4441 |
2009 | ||||||||
Authors :
James Brugarolas
Journal : Journal of Clinical Oncology Journal Reference count : 5 Volume : 26 Pages : 5653-5654 |
2008 | ||||||||
Renal-Cell Carcinoma — Molecular Pathways and Therapies Authors : James BrugarolasJournal : New England Journal of Medicine Journal Reference count : 14 Volume : 356 Pages : 185-187 |
2007 | ||||||||
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes Authors : James Brugarolas , William G KaelinJournal : Cancer Cell Journal Reference count : 48 Volume : 6 Pages : 7-10 |
2004 | ||||||||
p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells Authors : James Brugarolas , Roderick T. Bronson , Tyler JacksJournal : The Journal of Cell Biology Journal Reference count : 83 Volume : 141 Pages : 503-514 |
1998 | ||||||||
Double indemnity: p53, BRCA and cancer Authors : James Brugarolas , Tyler JacksJournal : Nature Medicine Journal Reference count : 24 Volume : 3 Pages : 721-722 |
1997 |